Silo Pharma (NASDAQ:SILO – Get Free Report) and Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.
Earnings and Valuation
This table compares Silo Pharma and Jupiter Neurosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silo Pharma | $70,000.00 | 42.82 | -$4.23 million | ($4.36) | -0.43 |
| Jupiter Neurosciences | $20,000.00 | 84.17 | -$8.65 million | ($19.12) | -0.10 |
Silo Pharma has higher revenue and earnings than Jupiter Neurosciences. Silo Pharma is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and target prices for Silo Pharma and Jupiter Neurosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
| Jupiter Neurosciences | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Silo Pharma and Jupiter Neurosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
| Jupiter Neurosciences | N/A | N/A | -246.66% |
Insider & Institutional Ownership
5.6% of Silo Pharma shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by company insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Silo Pharma has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Jupiter Neurosciences has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500.
Summary
Jupiter Neurosciences beats Silo Pharma on 6 of the 11 factors compared between the two stocks.
About Silo Pharma
Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on developing therapeutics that combine traditional pharmaceutical approaches with psychedelic research. The company’s programs are intended to address conditions involving pain, inflammation, neurological disorders, and mental health. Silo Pharma’s pipeline has included SP-26, an investigational ketamine-based implant designed to provide sustained drug delivery and being explored for conditions such as fibromyalgia. Its research portfolio has also included intranasal formulations and other therapeutics targeting disorders such as post-traumatic stress disorder and Alzheimer’s disease.
About Jupiter Neurosciences
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) is a clinical-stage biotechnology company focused on developing therapies for diseases associated with neuroinflammation. The company’s research is centered on small-molecule drug candidates intended to address inflammatory processes affecting the central nervous system. Jupiter Neurosciences’ lead product candidate, JNS-101, is an orally administered, brain-penetrant compound being developed for its potential anti-inflammatory and neuroprotective effects.
Receive News & Ratings for Silo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
